AI Applications for Drug Discovery and Development is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Abraham Heifets
CEO at Atomwise, USA

Profile

Dr. Abraham Heifets is CEO and co-founder of Atomwise, where he invented the use of deep convolutional neural networks for drug discovery. Atomwise is the leader in using artificial intelligence (AI) and machine learning to discover new medicines, with over $3 billion in deals and more than 250 discovery collaborations running in 36 countries and across every major therapeutic area.


Abraham is an author on 24 papers, patents and patent applications, including an industry-leading paper identifying ubiquitous weaknesses in existing benchmarks for AI drug discovery. He has presented his work to the U.S. Government Accountability Office, the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence.


Abraham was a Massey Fellow at the University of Toronto—a center for AI innovation—and a Fellow of the Ontario Brain Institute. His doctoral work applied machine learning and classical AI techniques to organic synthesis planning, a long-standing challenge in chemistry.



Previously, Abraham researched high-performance data processing at IBM's T.J. Watson Research Center and contributed to the AI system of the world-champion robotic soccer team at Cornell University, from which he holds two previous degrees.


LinkedIn: https://www.linkedin.com/in/abrahamheifets/

Abraham Heifets's Network

Agenda Sessions

  • Discussion Panel: Consortia, big data and pre-competitive use

    , 11:00am
  • Discussion Panel: Challenges in the application of AI and Machine Learning in Drug Discovery - Different challenges for different entities

    , 8:30am